Skip to Content
Merck
CN

528900

2-Bromo-5-fluoroaniline

97%

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Linear Formula:
BrC6H3(F)NH2
CAS Number:
Molecular Weight:
190.01
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

2-Bromo-5-fluoroaniline, 97%

InChI

1S/C6H5BrFN/c7-5-2-1-4(8)3-6(5)9/h1-3H,9H2

SMILES string

Nc1cc(F)ccc1Br

InChI key

FWTXFEKVHSFTDQ-UHFFFAOYSA-N

assay

97%

mp

43-47 °C (lit.)

Application

2-Bromo-5-fluoroaniline may be used to synthesize:
  • orthobromothiobenzanilide of 5-fluoronitrobenzothiazole
  • 2-bromo-5-fluorobenzo[14C]nitrile
  • [3-14C]-5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
  • 2-bromo-5-fluoro-phenyl)-(2-methoxy-6-pentadecyl-benzyl)amine

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

230.0 °F - closed cup

flash_point_c

110 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Synthesis of novel benzylamine analogues of Anacardic acid as potent antibacterial agents.
Dubey PK.
Der Pharma Chemica, 3(6), 500-512 (2011)
Synthesis of isotopically labelled [3-14C]-and [3, 3-2H2]-5-fluoro-1, 3-dihydro-1-hydroxy-2, 1-benzoxaborole (AN2690), a new antifungal agent for the potential treatment of onychomycosis.
Baker SJ, et al.
Journal of Labelled Compounds & Radiopharmaceuticals, 50(4), 245-250 (2007)
T D Bradshaw et al.
Current medicinal chemistry, 11(8), 1009-1021 (2004-04-14)
This review traces the development of a series of potent and selective antitumour benzothiazoles from the discovery of the initial lead compound, 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) in 1995 to the identification of a clinical candidate, Phortress, scheduled to enter Phase 1

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service